INSM · INSMED Inc
$123.74
-2.59 (-2.05%)
At close · Aug 14
Market Cap
$27.02B
Shares
218.38M
INSMED Inc Earnings Call Transcripts
Every quarterly earnings call for INSMED Inc (INSM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲44.9%
$67.73M
−$131.15M
'22 Q3
22-10-27
▲5.7%
$59.30M
−$160.12M
'22 Q4
23-02-23
▲22.8%
$65.21M
−$159.76M
'23 Q1
23-05-04
▲18.4%
$77.23M
−$244.81M
'23 Q2
23-08-03
▲16.7%
$79.07M
−$158.93M
'23 Q3
23-10-26
▲41.1%
$83.69M
−$186.06M
'23 Q4
24-02-22
▲15.8%
$75.50M
−$157.09M
'24 Q1
24-05-09
▲17%
$90.34M
−$300.61M
'24 Q2
24-08-08
▲18.2%
$93.42M
−$220.52M
'24 Q3
24-10-31
▲24.8%
$104.44M
−$235.55M
'24 Q4
25-02-20
▲22.9%
$92.82M
−$256.58M
'25 Q1
25-05-08
▲18.9%
$107.42M
−$321.69M
'25 Q2
25-08-07
▲52.4%
$142.34M
−$370.02M
'25 Q3
25-10-30
▲152.6%
$263.84M
−$328.49M
'25 Q4
26-02-19
▲229.6%
$305.96M
−$163.56M
'26 Q1
26-05-07
LATEST
▲296.1%
$425.49M
−$13.24M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
INSMED Inc Q2 FY2026 Earnings Call
Confident tone
Brinsupri commercial launch
Revenue guidance raise
Raised peak sales estimates
Revenue
$425.49M
▲ 296.1% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
INSMED Inc Q1 FY2026 Earnings Call
Confident tone
BRINSUPRI Commercial Launch
Bronchiectasis Diagnosis Expansion / Disease Awareness
TPIP Phase III Development
Revenue
$305.96M
▲ 229.6% YoY Diluted EPS
$-0.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
INSMED Inc Q4 FY2025 Earnings Call
Confident tone
Brinsupri launch performance and trajectory
COPD/ashma overlap and undiagnosed bronchiectasis
Bronchiectasis market expansion opportunity (TAM)
Revenue
$263.84M*
▲ 152.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
INSMED Inc Q3 FY2025 Earnings Call
Confident tone
BRINSUPRI U.S. launch
BiRCh Phase II in CRS without nasal polyps
Gene therapy programs
Revenue
$142.34M
▲ 52.4% YoY Diluted EPS
$-1.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
INSMED Inc Q2 FY2025 Earnings Call
Confident tone
Brensocatib U.S. launch and label/PDUFA
TPIP Phase III planning across PAH, PH-ILD, IPF
Early-stage research engine and INDs
Revenue
$107.42M
▲ 18.9% YoY Diluted EPS
$-1.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
INSMED Inc Q1 FY2025 Earnings Call
Confident tone
Brensocatib FDA review and bronchiectasis launch readiness
Gene therapy program (fourth pillar)
TPIP Phase 2 in PAH
Revenue
$92.82M
▲ 22.9% YoY Diluted EPS
$-1.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
INSMED Inc Q4 FY2024 Earnings Call
Confident tone
Brensocatib launch readiness
Pipeline breadth and catalysts
TPIP clinical development
Revenue
$104.44M*
▲ 24.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
INSMED Inc Q3 FY2024 Earnings Call
Confident tone
Brensocatib NDA and launch preparation
TPIP in PAH and PH-ILD
ARIKAYCE commercial performance and ENCORE trial
Revenue
$93.42M
▲ 18.2% YoY Diluted EPS
$-1.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
INSMED Inc Q2 FY2024 Earnings Call
Revenue
$90.34M
▲ 17% YoY Diluted EPS
$-1.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
INSMED Inc Q1 FY2024 Earnings Call
Confident tone
TPIP PH-ILD Phase II safety results
TPIP PAH blinded Phase II data
Brensocatib ASPEN Phase III readout
Revenue
$75.50M
▲ 15.8% YoY Diluted EPS
$-1.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
INSMED Inc Q4 FY2023 Earnings Call
Confident tone
Brensocatib (ASPEN readout) and bronchiectasis opportunity
TPIP program in PAH and PH-ILD
Capital position / ATM equity program
Revenue
$83.69M*
▲ 41.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
INSMED Inc Q3 FY2023 Earnings Call
Revenue
$79.07M
▲ 16.7% YoY Diluted EPS
$-1.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
INSMED Inc Q2 FY2023 Earnings Call
Revenue
$77.23M
▲ 18.4% YoY Diluted EPS
$-1.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
INSMED Inc Q1 FY2023 Earnings Call
Revenue
$65.21M
▲ 22.8% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
INSMED Inc Q4 FY2022 Earnings Call
Revenue
$59.30M*
▲ 5.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
INSMED Inc Q3 FY2022 Earnings Call
Revenue
$67.73M
▲ 44.9% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
INSMED Inc Q2 FY2022 Earnings Call
Revenue
$65.22M
▲ 43.8% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
INSMED Inc Q1 FY2022 Earnings Call
Revenue
$53.11M
▲ 32.1% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
INSMED Inc Q4 FY2021 Earnings Call
Revenue
$56.12M*
▲ 35.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
INSMED Inc Q3 FY2021 Earnings Call
Revenue
$46.76M
▲ 7.1% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
INSMED Inc Q2 FY2021 Earnings Call
Revenue
$45.37M
▲ 6.8% YoY Diluted EPS
$-1.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
INSMED Inc Q1 FY2021 Earnings Call
Revenue
$40.21M
▲ 9.1% YoY Diluted EPS
$-0.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
INSMED Inc Q4 FY2020 Earnings Call
Revenue
$41.41M*
▼ 9.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
INSMED Inc Q3 FY2020 Earnings Call
Revenue
$43.64M
▲ 12.2% YoY Diluted EPS
$-0.63
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
INSMED Inc Q2 FY2020 Earnings Call
Revenue
$42.49M
▲ 41.8% YoY Diluted EPS
$-0.64
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
INSMED Inc Q1 FY2020 Earnings Call
Revenue
$36.86M
▲ 68.3% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
INSMED Inc Q4 FY2019 Earnings Call
Revenue
$45.71M
▲ 364.7% YoY Gross margin
81.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1104506
CUSIP
457669307
13F (30d)
609 filings
602 filers
Visit website
Investor relations